This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, X. Articles by Thorpe, P. E. Search for Related Content PubMed PubMed Citation Articles by Huang, X. Articles by Thorpe, P. E.

A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice

¹ Department of Pharmacology and Simmons and Hamon Cancer Centers, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas and ² Lexicon Genetics, Inc., the Woodlands, Texas

Requests for reprints: Philip E. Thorpe, Department of Pharmacology and Simmons and Hamon Cancer Centers, University of Texas Southwestern Medical Center at Dallas, 2201 Inwood Road NC7.304, Dallas, TX 75390-8594. Phone: 214-648-1268; Fax: 214-648-1613; E-mail: Philip.Thorpe{at}UTSouthwestern.edu.

Anionic phospholipids, principally phosphatidylserine, become exposed on the external surface of viable vascular endothelial cells in tumors, providing an excellent marker for tumor vascular targeting. We recently raised an IgG monoclonal antibody, 3G4, which binds to anionic phospholipids in a ß2-glycoprotein I–dependent manner. It inhibited tumor growth in a variety of rodent tumor models by stimulating antibody-dependent cellular cytotoxicity toward tumor vessels. In the present study, we tested the hypothesis that docetaxel, which is known to have antivascular effects on tumors, might induce exposure of anionic phospholipids on tumor vasculature and, thus, enhance the antitumor activity of 3G4. Treatment of human umbilical vascular endothelial cells with subtoxic concentrations of docetaxel (20 pmol/L) in vitro caused anionic phospholipids to be externalized without inducing apoptosis. Docetaxel treatment of mice increased the percentage of tumor vessels that expose anionic phospholipids from 35% to 60%. No induction of phosphatidylserine was observed on vessels in normal tissues even after systemic treatment with docetaxel. Treatment of mice bearing orthotopic MDA-MB-435 human breast tumors with 3G4 plus docetaxel inhibited tumor growth by 93%. Treatment of mice bearing disseminated MDA-MB-435 tumors with 3G4 plus docetaxel reduced the average number of tumor colonies in the lungs by 93% and half the animals did not develop tumors. In both tumor models, the antitumor effect of the combination was statistically superior (P < 0.01) to that of docetaxel or 3G4 alone. Combination therapy reduced the tumor vessel density and plasma volume in tumors to a greater extent than did the individual drugs. The combination therapy was no more toxic to the mice than was docetaxel alone. These results indicate that, as an adjuvant therapy, 3G4 could enhance the therapeutic efficacy of docetaxel in breast cancer patients.

This article has been cited by other articles:

				J. He, Y. Yin, T. A. Luster, L. Watkins, and P. E. Thorpe Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma Clin. Cancer Res., November 15, 2009; 15(22): 6871 - 6880. [Abstract] [Full Text] [PDF]

				K. Al-Nedawi, B. Meehan, R. S. Kerbel, A. C. Allison, and J. Rak Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR PNAS, March 10, 2009; 106(10): 3794 - 3799. [Abstract] [Full Text] [PDF]

				M. Jennewein, M. A. Lewis, D. Zhao, E. Tsyganov, N. Slavine, J. He, L. Watkins, V. D. Kodibagkar, S. O'Kelly, P. Kulkarni, et al. Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine Clin. Cancer Res., March 1, 2008; 14(5): 1377 - 1385. [Abstract] [Full Text] [PDF]

				J. He, T. A. Luster, and P. E. Thorpe Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids Clin. Cancer Res., September 1, 2007; 13(17): 5211 - 5218. [Abstract] [Full Text] [PDF]

				D. S. Dace, P. W. Chen, H. Alizadeh, and J. Y. Niederkorn Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner J. Leukoc. Biol., February 1, 2007; 81(2): 421 - 429. [Abstract] [Full Text] [PDF]

				T. A. Luster, J. He, X. Huang, S. N. Maiti, A. J. Schroit, P. G. de Groot, and P. E. Thorpe Plasma Protein beta-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells J. Biol. Chem., October 6, 2006; 281(40): 29863 - 29871. [Abstract] [Full Text] [PDF]

				D. G. Duda Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res., April 15, 2006; 66(8): 3967 - 3970. [Abstract] [Full Text] [PDF]

				P. A. Campochiaro and the First ARVO/Pfizer Institute Working Group Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 462 - 474. [Full Text] [PDF]